Medincell Aktie

16,52 EUR +0,02 EUR +0,12 %

23.12.2024

FSE

16,76 EUR -0,04 EUR -0,24 %

23.12.2024

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.489,88 Mio. EUR

Div. Rendite0,00%

WKNA2N6VA

ISINFR0004065605

SymbolMDCLF

Medincell Aktien News

Sortieren:Datum Meistgelesen

12.12.24BusinesswireMedincell to Join the Euronext SBF 120 Index

09.12.24BusinesswireMedincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacement

06.11.24BusinesswireMedincell: 25% Raise in 2024 UZEDY® Revenue Outlook & Key Milestone Reached for Olanzapine LAI Clinical Phase 3

WerbungMedincell-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

04.11.24BusinesswireMedincell’s Partner Teva Unveils New Phase 3 Positive Results for Olanzapine LAI, and Presents Real-World Data on UZEDY® at Psych Congress 20241

23.09.24BusinesswireMedincell’s Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

23.09.24BusinesswireMedincell’s Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

05.09.24BusinesswireMedincell’s Partner Teva Provides New Update on Pivotal Clinical Phase 3 of Investigational Olanzapine Long-Acting Injectable (LAI)

03.09.24BusinesswireMedincell Announces Progress in the Development of its Products Portfolio and R&D Pipeline

31.07.24BusinesswireMedincell’s partner Teva provides update on pivotal clinical Phase 3 of investigational Olanzapine Long-Acting Injectable (LAI) and UZEDY® commercial progress

08.05.24BusinesswireTeva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia

16.04.24BusinesswireMedincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies

08.04.24BusinesswireUnitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria

31.01.24BusinesswireMedinCell’s Partner Teva Provides Guidance for UZEDY in 2024 and an Update on the Treatment-Candidate of Olanzapine Long-Acting Injectable (LAI)

09.01.24BusinesswireMedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)

13.11.23BusinesswireMedinCell Applauds Teva and Royalty Pharma Collaboration to Further Accelerate Olanzapine LAI Program (Codename: mdc-TJK or TEV-‘749)

30.08.23BusinesswireMedinCell announces successful completion of patient enrollment in the Phase 3 study of F14 (mdc-CWM), a first-in-class therapy for localized pain relief after Total Knee Replacement

04.05.23BusinesswireMedinCell: mdc-TJK's (Teva's codename: TEV-44749) Phase 1 study pharmacokinetics to be presented for the first time by Teva at SIRS 2023 (May 11-15, 2023, Toronto, Canada)

24.01.23BusinesswireInitiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell’s technology (program mdc-TJK)

05.01.23BusinesswireMedinCell announces positive results for the SAIVE clinical study in prevention of Covid-19 infection in a contact-based population

30.11.22BusinesswireAdditional US$ 4 Million Received for Next Development Steps of MedinCell's 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive

23.11.22BusinesswireFrance : EIB and MedinCell Sign a New €40 Million Loan Agreement to Support Development of Innovative Treatments

07.11.22BusinesswireMedinCell announces the initiation of Phase 3 study of F14 (mdc-CWM), a therapeutic first-in-class that aims to provide weeks of localized pain relief after Total Knee Replacement

13.09.22BusinesswireMedinCell Signs a Licence Agreement With the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission

05.09.22BusinesswireMedinCell Secures Additional 20 Million Euros Financing With the European Investment Bank (EIB)

29.08.22BusinesswirePhase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell’s Technology

17.08.22BusinesswireAn Impact Company Committed to Improving the Health of Patients Worldwide, MedinCell Publishes Its 2021-2022 ESG Annual Report

09.05.22BusinesswireMedinCell: US Pharma Development Expert Richard Malamut, MD Becomes Chief Medical Officer

03.05.22BusinesswireMedinCell’s Partner Teva Provides Additional Information Regarding the New Drug Application for mdc-IRM

20.04.22BusinesswireMedinCell provides additional information regarding the new drug application for MDC-IRM

28.03.22BusinesswireMedinCell: Inclusion of First Participants in New Covid-19 Prophylaxis Clinical Trial SAIVE

Medincell News

Medincell News: auf dieser Seite finden Sie alle Medincell News und Nachrichten zur Medincell Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Medincell News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Medincell News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.